The White House has directed visa officers to consider common health ailments, including obesity and diabetes, when deciding ...

Medicare will start covering obesity drugs for the first time, which could open access to millions of seniors and spur more ...

Subcutaneous injections of an investigational, selective long-acting amylin receptor agonist led to clinically meaningful ...

The Food Research & Action Center calls SNAP item bans misguided, arguing the better path is incentives and access rather ...

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices ...

This expands the criteria beyond communicable diseases, giving consular officials broader authority to reject applicants ...

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

Prescriptions for GLP-1 receptor agonists in cancer patients have increased despite lack of clinical guidance. The overall ...

Dr. Mehmet Oz, administrator for Medicare and Medicaid Services, says the deal is being done to "create a moral playground ...

Eli Lilly and Novo Nordisk officials have agreed to lower the cost of GLP-1 obesity drugs for Medicaid and Medicare ...

The Trump administration is expected to announce deals with Eli Lilly and Novo Nordisk to cut prices of some weight loss ...